Compare ODC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ODC | ENGN |
|---|---|---|
| Founded | 1941 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.2M | 605.5M |
| IPO Year | N/A | N/A |
| Metric | ODC | ENGN |
|---|---|---|
| Price | $57.88 | $11.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.71 |
| AVG Volume (30 Days) | 68.0K | ★ 399.3K |
| Earning Date | 03-10-2026 | 03-09-2026 |
| Dividend Yield | ★ 1.42% | N/A |
| EPS Growth | ★ 17.33 | N/A |
| EPS | ★ 3.63 | N/A |
| Revenue | ★ $478,113,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.95 | ★ N/A |
| Revenue Growth | ★ 5.29 | N/A |
| 52 Week Low | $41.37 | $2.65 |
| 52 Week High | $69.76 | $12.25 |
| Indicator | ODC | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 69.59 | 64.90 |
| Support Level | $47.51 | $8.68 |
| Resistance Level | $60.00 | $12.25 |
| Average True Range (ATR) | 1.57 | 0.83 |
| MACD | 0.80 | 0.27 |
| Stochastic Oscillator | 82.70 | 72.42 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.